Therapeutically active fluoro substituted benzimidazoles
申请人:Aktiebolaget Hassle
公开号:US05049674A1
公开(公告)日:1991-09-17
The novel compounds of the formulas I and I' ##STR1## wherein F is in 5 or 6 position and ##STR2## wherein in both formulas R is the group --CH.sub.2 OCOOR.sup.1, wherein R.sup.1 is a straight or branched alkyl containing 1-6 carbon atoms or benzyl, or R.sup.1 is the group ##STR3## --(CH.sub.2).sub.n COOH or --(CH.sub.2).sub.n SO.sub.3 H wherein n is 1-6 and physiologically acceptable salts thereof as well as intermediates, pharmaceutical compositions containing such compounds as active ingredient, and the use of the compounds in medicine.
Structure−Activity Relationship of 2-[[(2-Pyridyl)methyl]thio]-1<i>H</i>- benzimidazoles as Anti <i>Helicobacter pylori </i>Agents in Vitro and Evaluation of their in Vivo Efficacy
作者:Thomas C. Kühler、Marianne Swanson、Vladimir Shcherbuchin、Håkan Larsson、Björn Mellgård、Jan-Eric Sjöström
DOI:10.1021/jm970165r
日期:1998.5.1
A relationship between the structure of 21 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazoles (6) and their anti Helicobacter pylori activity expressed as minimum bactericidal concentration (MBC) values is described. Observed MBCs ranged from 256 to 1 microg/mL. The structure-activity relationship (SAR) showed that larger and more lipophilic compounds, especially compounds with such substituents in the
Therapeutically active cyclopropyl substituted compound
申请人:Aktiebolaget Hassle
公开号:US05039808A1
公开(公告)日:1991-08-13
The novel compound 5-fluoro-2[[(4-cyclopropylmethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimid azole and physiologically acceptable salts thereof as well as intermediates, pharmaceutical compositions containing the compound as active ingredient, and the use of the compound in medicine.